tbuckley/cabot-search huggingface dataset:
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
Authors: Claire N. Harrison, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Christof Scheid, James P. Dean, Huafeng Zhou, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Jyoti Nangalia, Adam Mead, Ruben A. Mesa
Journal: Journal of Clinical Oncology (2016)

7011 Background: Many pts with MF present with cytopenias, which are often progressive, and effective treatment (Tx) options that do not induce myelosuppression are limited. PAC, an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, was not associated with clinically significant myelosuppression in early trials. PERSIST-1 compares PAC vs BAT, excluding JAK2 inhibitors, in intermediate (Int)- to high-risk pts with MF, regardless of BL platelets (plt). At wk 24, a significantly greater proportion of PAC- vs BAT-treated pts achieved ≥ 35% spleen volume reduction (ITT: 19.1% vs 4.7%, p = 0.0003, 1º end point) and ≥ 50% reduction in Total Symptom Score (TSS; ITT: 24.5% vs 6.5%, p < 0.0001). This analysis examines long-term outcomes for pts with BL thrombocytopenia defined as plt < 100,000/μL or < 50,000/μL. Methods: Pts were randomized 2:1 to oral PAC 400 mg qd or BAT and stratified by DIPSS risk and plt count. Pts had splenomegaly ≥ 5 cm, TSS ≥ 13, and ANC > 500/µL. There were no restrictions on BL plt or hemoglobin. Pts could crossover from BAT to PAC after wk 24 or upon disease progression prior to wk 24. Results: At BL, ~1/3 of pts had thrombocytopenia (Table). Among evaluable PAC-treated pts on Tx at wk 60: 26% and 21% of pts with BL plt < 100,000/μL or < 50,000/μL achieved SVR ≥ 35%, respectively. No BAT-treated pt with BL plt < 100,000/μL achieved SVR ≥ 35%. At wk 48 (last assessment per protocol) 61% and 78% of evaluable PAC-treated pts with BL plt < 100,000/μL or < 50,000/μL achieved ≥ 50% reduction in TSS, respectively, increased from 42% and 32% at wk 24. In PAC-treated pts with thrombocytopenia, mean plt count and hemoglobin increased from BL to wk 60 (Table). Following crossover from BAT to PAC, of evaluable pts with BL plt < 100,000/μL or < 50,000/μL, 31% and 31% achieved SVR ≥ 35% (best response after crossover). Conclusions: In pts with MF and BL thrombocytopenia, Tx with PAC led to durable reductions in spleen volume and symptom burden including in pts with BL plt < 50,000/μL. Clinical trial information: NCT01773187. Plt < 50,000/μL Plt < 100,000/μL n PAC n BAT n PAC n BAT Mean plt, count/μL BL 35 29,700 15 30,100 68 56,100 31 50,000 Wk 60 12 44,500 0 – 30 68,900 0 – Mean hemoglobin, g/dL BL 35 9.8 15 9.6 72 10.0 33 9.3 Wk 60 13 9.8 0 – 31 10.5 0 –
P3.03-036 Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)
Authors: Herbert Pang, Kang Yan, Robert Kratzke, Thomas Stinchcombe, Jeffrey Crawford, Hedy Kindler, Everett Vokes, Xiaofei Wang
Journal: Journal of Thoracic Oncology (2017)
P1.08-042 Overall Survival and Tumor Recurrence after VATS Lobectomy of N1 Positive NSCLC is Equal to Open Resection
Authors: Herbert Maier, Caecilia Ng, Florian Kocher, Magdalena Sacher, Gregor Laimer, Paolo Lucciarini, Thomas Schmid, Florian Augustin
Journal: Journal of Thoracic Oncology (2017)
M19 Patient perspectives of an ambulatory pleural service
Authors: N Devani, U Gupta, R Kaiser, RH Johns
Journal: Thorax (2016)

<h3>Background and objectives</h3> Barking, Havering and Redbridge University Trust (BHRUT) serves a population of 750,000 patients with a large burden of pleural disease. Patients admitted and requiring pleural drainage usually results in a long length of stay of around 7–10 days. Outpatient ambulatory management of undiagnosed and known malignant pleural effusions is increasing nationally in the UK through development of pleural clinics. Previous reports have demonstrated these to be financially efficacious and avoid hospitalisation. We sought to demonstrate that they are also well received and favoured by patients. <h3>Methods</h3> In December 2015, an outpatient weekly pleural aspiration service was established receiving referrals directly from respiratory outpatients, A&amp;E and acute medicine. We prospectively audited patients attending this service between December 2015 and June 2016. Patients were asked to complete an in-depth questionnaire to assess their experience on the day, any procedural discomfort and attitudes toward such an outpatient service. <h3>Results</h3> 81 patients attended our service over this period. Median age was 74 (range 30–92), 40% female. 58 patients returned a completed questionnaire. 86% of patients were seen within a week of referral with the rest waiting less than 2 weeks. The majority (74%, n = 43) of patients did not notice any deterioration in their symptoms during this wait. Median pain score was 3(range 1–10). 78% (n = 45) of patients felt they could continue with their normal activities post procedure. Only 2 patients would have preferred to undergo the procedure as an inpatient citing frailty as the reason. 98% (n = 57) of patients felt that an outpatient pleural service was a good idea. 78% (n = 45) rated the service as excellent, 17% (n = 10) as ‘above average’ and only 5% (n = 3) as ‘average.’ <h3>Conclusions</h3> Outpatient management of pleural effusions is favoured by patients with most rating our service as excellent. Patients are seen promptly with the majority reporting no deterioration in their symptoms during the wait. The procedure is well tolerated and allows patients to continue with their normal daily activities. In addition to important financial benefits of reducing hospital bed-days in patients with pleural effusions, our newly established service has been shown to be beneficial in promoting a positive patient experience.
Retrospective analysis of neoadjuvant chemoradiotherapy for esophageal cancer: The Knight Cancer Institute experience.
Authors: Faisal A Siddiqui, James P. Dolan, John G. Hunter, Miriam A. Douthit, Lisa M. Bloker, John M Holland, Charles R. Thomas
Journal: Journal of Clinical Oncology (2012)

126 Background: Neoadjuvant chemoradiotherapy (NAT) followed by esophagectomy has been established as standard of care for early stage (II – III), resectable esophageal cancer (EC). Patients (pts) treated with NAT are more likely to be downstaged and have a complete (R0) resection. Additionally, pts with aggressive disease are more likely to progress during NAT and, consequently, avoid unnecessary surgery. The aim of the current report was to analyze the outcomes of trimodality therapy at the Knight Cancer Institute. Methods: A retrospective study of 124 pts who underwent NAT followed by esophagectomy for EC from 1999-2010 at our institution was performed. All pts were initially staged by imaging (EUS, CT and/or PET imaging) prior to commencing treatment. After esophagectomy, pathological staging was compared to initial staging to determine the effect of NAT. Results: There were 25 women and 99 men. Initial staging is shown in the table below. Patients received cisplatin, oxaliplatin or carboplatin with 5-FU plus concurrent radiotherapy (RT). RT total dose of 45 Gy to the tumor and regional nodes was given in 1.8 Gy daily fractions, followed by a boost to the tumor for final dose 50.4-54 Gy. 27 (21.8%) of the pts had a pathologic complete response. Additionally, 54 (43.6%) pts were downstaged by chemoradiation. Of the pts that had complete remission or were downstaged, pre-treatment clinical stage was Stage II (22 pts), Stage III (55 pts), and Stage IVa (4 pts). Conclusions: NAT was effective in complete remission or downstaging of two-thirds (81) pts, including 4 pts that were initially unresectable (Stage IVa) and successfully underwent subsequent esophagectomy. As has been shown previously, NAT is effective for downstaging prior to esophagectomy making it more likely that pts will undergo R0 resection. This study also demonstrated that some pts with clinically unresectable tumors could undergo successful esophagectomy after NAT. [Table: see text]
Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Authors: Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R. Cogle, Steven D. Gore, Keshava J. Kumar, Barry S. Skikne, Kyle J. MacBeth
Journal: Blood (2012)
P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer
Authors: Alona Zer, Mike Sung, Kanwalpreet Walia, Leila Khoja, Manjula Maganti, Catherine Labbe, Frances Shepherd, Penelope Bradbury, Ronald Feld, Geoffrey Liu, Melissa Iazzi, Dianne Zawisza, Nazanin Nouriany, Natasha Leighl
Journal: Journal of Thoracic Oncology (2017)
P3.02c-039 Endocrinological Side-Effects of Nivolumab in Advanced Non-Small Cell Lung Cancer
Authors: Giovanni Rossi, Manuela Albertelli, Elena Nazzari, Erka Rijavec, Carlo Genova, Giulia Barletta, Federica Biello, Claudia Maggioni, Maria Giovanna Dal Bello, Diego Ferone, Francesco Grossi
Journal: Journal of Thoracic Oncology (2017)
S130 The prevalence of undiagnosed copd on spirometry and emphysema on low-dose ct scans in a lung cancer screening demonstration pilot: a teachable moment?
Authors: C Horst, M Ruparel, S Quaife, A Ahmed, M Taylor, A Bhowmik, S Burke, P Shaw, A McEwen, J Waller, DR Baldwin, N Navani, R Thakrar, SM Janes
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Chronic obstructive pulmonary disease (COPD) and emphysema are considerably under-diagnosed conditions. Low dose CT (LDCT) for lung cancer screening, if implemented, may provide an opportunity for earlier diagnosis of smoking-related conditions, in addition to lung cancer. Data gathered in a lung cancer screening demonstration pilot was analysed to look at COPD-related radiological changes and their relationship with patients' pre-existing diagnoses, spirometry results and smoking status. The aims were to better understand these interlinked conditions and identify the potential for earlier diagnosis and management of smoking cessation interventions for these conditions. <h3>Methods</h3> Data were collected as part of the Lung Screen Uptake Trial. Smokers and recent former smokers (quit &lt;5 years) aged 60–75 were invited to a 'lung health check' via their general practitioner (GP). Data on pre-existing diagnoses, smoking status and pre-bronchodilation spirometry, categorised according to the National Institute for Clinical Excellence (NICE) criteria, were collected. Patients who met the eligibility criteria for screening went on to have LDCT. Results were analysed for frequencies, and confidence intervals calculated for the most significant results. <h3>Results</h3> 275 patients responded to an invitation to attend a 'lung health check' in the first six months of recruitment. 149 (54.2%) had values consistent with COPD on spirometry. 106 [71.1%, (95% CI: ± 7.3%)] of these individuals were not aware of a diagnosis of COPD, and 81 (76.4%) were current smokers (Figure 1). Of the 103 individuals who had emphysema and no suspicious lesion on LDCT, 74 [71.8%, (95% CI: ± 8.7%)] were not aware of a diagnosis of COPD or emphysema. 55 (74.3%) of these were current smokers, and 33 (44.6%) had preserved spirometry (Table 1). <h3>Conclusion</h3> Our data demonstrate the considerable burden of undiagnosed COPD in at-risk groups (38.5% of all screened individuals), and show the prevalence of emphysematous change in those patients without a pre-existing, self-reported diagnosis of COPD or with preserved spirometry. Early diagnosis and CT evidence of smoking damage may provide the opportunity to co-implement supportive smoking cessation interventions, earlier medical intervention and prevention of further progression of disease through improved management of these conditions.
P87 The use of a virtual clinic to speed up and improve the cancer diagnostic pathway – 2 year experience
Authors: A McIver, N Maddock, J Dunbar, J Hughes, MJ Ledson, C Smyth, MJ Walshaw
Journal: Thorax (2016)

In order to speed up the diagnostic pathway, in January 2014 we set up a “straight to CT” service for patients with suspected lung cancer from primary care, where positive scans undergo immediate chest physician review to decide the next diagnostic test and a lung cancer nurse specialist (CNS) offers the patient a telephone assessment to plan this. We have looked at the utility of this “virtual clinic” in the management of our patients with lung cancer over the first 2 years, in particular paying attention to patient uptake and satisfaction, and outcomes. Of about 300 patients annually who have been triaged in this way, 82% have chosen the virtual clinic, 13% preferred or the CNS advised a outpatient appointment, 4% required immediate inpatient referral, and the remaining and 1% were referred back to the GP as outpatient intervention not felt appropriate (too unwell). Overall, 75% subsequently were diagnosed with lung cancer. For those patients who chose the virtual clinic consultation, feedback has been overwhelmingly positive. This has been captured qualitatively at the time and at subsequent events e.g. patients report feeling well informed and supported, and quantitatively by an ongoing survey: 98% prefer the telephone clinic versus clinic appointment, 97% felt prepared for next test. This study has shown that performing a number of diagnostic investigations using a telephone support is not only feasible but preferred by patients with suspected lung cancer. By avoiding unnecessary clinic attendances it improves patient convenience, speeds up the diagnostic pathway and reduces unnecessary costs. This early CNS assessment and interventions reduces the level/scope of patient concerns prior to the time of diagnosis, this has further significance to the team formalising the Holistic Needs Assessment process. CNSs are best placed to do the consultations as they have the specialist skills and knowledge of the local clinical pathways, tests, disease symptomology and ultimately provide the continuity throughout the diagnostic pathway through to treatment and we recommend this to other cancer units.
P3.03-054 Review and Descriptive Analysis of 140 Patients Diagnosed with Malignant Mesothelioma at Consorci Sanitari Parc Tauli
Authors: Juan Carlos Pardo Ruiz, Yolanda Garcia Garcia, Maria Marin Alcala, Paula Ribera Fernandez, Marta Ferrer Cardona, Helena Oliveres Montero De Novoa, Clara Martinez Vila, Jose Manuel Cabrera Romero, Julia Giner Joaquin, Elsa Dalmau Portulas, Ismael Macias Declara, Eugeni Saigi Grau
Journal: Journal of Thoracic Oncology (2017)
P3.06-008 Employing Remote Web Consenting and Social Media to Facilitate Enrollment to an International Trial on Young Lung Cancer
Authors: Barbara Gitlitz, Alicia Sable-Hunt, Steven Young, Andreas Kogelnik, Danielle Hicks, Deborah Morosini, Tiziana Vavala, Marisa Bittoni, S. Lani Park, Silvia Novello, Geoffrey Oxnard, Bonnie Addario
Journal: Journal of Thoracic Oncology (2017)
First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors.
Authors: D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, J. Kaufmann, J. Drevs
Journal: Journal of Clinical Oncology (2011)

3057 Background: Atu027 is a novel RNAi therapeutic based on cationic lipoplexes containing chemically stabilized siRNAs, which targets PKN3 gene expression in the vascular endothelium. PKN3 acts as a downstream effector of PI3K-signaling pathway and is implicated in controlling cellular morphology and locomotion in endothelial and cancer cells. Preclinical data obtained in various cancer mouse models revealed target-specific, RNAi-mediated silencing of PKN3 expression and significant inhibition of tumor progression and metastasis formation. Methods: Patients (pts) (ECOG PS 0-2) received Atu027 as a single 4h-infusion with 3wks follow-up, and were thereafter treated twice weekly over another four week period. Upon SD, pts were given the opportunity to continue until PD. Dose escalation was accompanied by assessment of data related to toxicity and pharmacokinetics (PK). Results: The study design comprises 11 escalating doses. To date, 21 pts have received Atu027 of seven dose levels up to 0.120 mg/kg. Mean age = 62.4 years (range 29-81), 12 female, 9 male. No premedication was required. No cytokine activation (TNF-α, IL-1β, IFN-γ, IL-6) was observed. In some subjects transient activation of the complement system (C3a, Bb, sC5b-9) was found, but without any clinical relevance. Preliminary PK-data showed dose-dependent increase in plasma siRNA as well as lipid levels. Across the dose levels tested, Atu027 was generally well-tolerated. Adverse events possibly related to Atu027 were fatigue grade (G)1 (4pts), hair loss G1 (2pts), sweating G1 (1pt), and abdominal pain G2 (1pt). G3 AEs not considered as DLTs were elevated lipase (1 pt, DL2) and diarrhea (1 pt, DL5). No dose limiting toxicities (DLTs) were seen so far. Stable disease after 3 months was observed in 6 pts. Two pts with neuroendocrine cancer had disease stabilization for 9 months, and partial regression of pulmonary metastases, respectively. Another patient with breast cancer had regression of liver metastases. Conclusions: Atu027 is well-tolerated and antitumor activity has been observed. Accrual is ongoing to determine the MTD of Atu027.
A Decade of Improvement in Neonatal Intensive Care
Authors: Scott A. Lorch
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis
Authors: P. P. Major, R. J. Cook, B.-L. Chen, M. Zheng
Journal: Journal of Clinical Oncology (2004)

8058 Background: Bone metastases are common in patients with breast or prostate cancer and cause significant pain and skeletal morbidity. The need for radiation to bone to treat pain or prevent a fracture is a significant clinical event associated with disease progression and quality-of-life decline. Therefore, radiation to bone was included in the composite endpoints describing skeletal morbidity in recent clinical trials of zoledronic acid. Herein, a statistically robust nonparametric method was used to measure the cumulative burden of radiation to bone over the entire course of follow-up to evaluate the benefit of 4-mg zoledronic acid in patients with breast or prostate cancer enrolled in 2 large, randomized, phase III trials. We have previously reported by this method that zoledronic acid significantly reduces the overall cumulative incidence of skeletal complications compared with placebo or pamidronate (Pam) in these patient populations. Methods: These trials were GCP-compliant, and patients gave written informed consent. Patients received 4 mg zoledronic acid via 15-minute infusion every 3–4 weeks for 2 years. Comparators were 90 mg Pam via 2-hour infusion (breast cancer) or placebo (prostate cancer). Survival-adjusted multiple event analysis was performed via the methods of Cook et al. (Stat Med 1997;16;911–924) and Ghosh and Lin (Biometrics 2000;56:554–562). Results: In patients with breast cancer (n = 766), 4 mg zoledronic acid was superior to 90 mg Pam and significantly reduced the cumulative mean number of administrations of radiation to bone by 35.4% at 25 months (P = .003), adding to the benefit achieved with Pam. Similarly, in patients with prostate cancer, 4 mg zoledronic acid significantly reduced the cumulative mean number of administrations of radiation to bone by 33.2% compared with placebo at 24 months (P = .034). Conclusion: This new, robust method provides a simple graphic representation of the cumulative need for radiation therapy and reveals the significant reduction in need for radiation therapy achieved with zoledronic acid in breast or prostate cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Novartis (US)
P1.02-002 Is T790M Mutation A “Regulator” for EGFR Signal Pathway Not an Oncogene?
Authors: Zheng Wang, Dongge Liu, Yuankai Shi, Xiaohong Han, Hongfeng Tong, Qingjun Wu, Jianguang Zhang, Tianyang Wang, David Cram
Journal: Journal of Thoracic Oncology (2017)
Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study
Authors: Thomas Gaisl, Cecilia Giunta, Daniel J Bratton, Kate Sutherland, Christian Schlatzer, Noriane Sievi, Daniel Franzen, Peter A Cistulli, Marianne Rohrbach, Malcolm Kohler
Journal: Thorax (2017)

<h3>Background</h3> Patients with the connective tissue disorder Ehlers-Danlos syndrome (EDS) often suffer from fatigue, excessive daytime sleepiness and impaired quality of life. Obstructive sleep apnoea (OSA) may be an underlying cause for these symptoms but its prevalence in this population is unclear. <h3>Methods</h3> In this prospective parallel-cohort study, we included 100 adult patients with EDS (46% hypermobile-type, 35% classical-type and 19% other), which were one-to-one matched to 100 healthy adult controls according to sex, age, weight and height. Participants underwent structured interviews (including short-form 36) and level-3 respiratory polygraphy. OSA was defined as apnoea–hypopnea index ≥5/hour. Photographic craniofacial phenotyping was conducted in a subgroup. Conditional logistic regression was used to compare the prevalence of OSA. <h3>Results</h3> In patients with EDS, OSA prevalence was 32% versus 6% in the matched control group (OR 5.3 (95% CI 2.5 to 11.2); p&lt;0.001). The EDS group reported impaired quality of life in all dimensions (p&lt;0.05) and significantly higher excessive daytime sleepiness measured by the Epworth Sleepiness Scale (median (quartiles) 11 (7–14) vs 7 (5–10); p&lt;0.001). OSA severity was positively associated with daytime sleepiness and lower quality of life in the EDS group. There was no evidence of a difference between the two study groups in terms of craniofacial phenotypes. <h3>Conclusions</h3> The prevalence of OSA is higher in patients with EDS than in a matched control group. This is of clinical relevance as it is associated with fatigue, excessive daytime sleepiness and impaired quality of life. Further studies are needed to assess the clinical benefit of OSA treatment in patients with EDS. <h3>Trial registration number</h3> NCT02435745.
P3.04-024 Long-Term Outcome of Sublobar Resection versus Lobectomy for Stage I and II Non-Small Cell Lung Cancer
Authors: Su Kyung Hwang, Seung-Il Park, Dong-Wan Kim, Yong-Hee Kim, Se Hoon Choi, Hyeong Ryul Kim
Journal: Journal of Thoracic Oncology (2017)